Negative symptoms and neuroleptics in catatonic schizophrenia.
The association between neuroleptic treatment and the negative symptom dimension (ND) was evaluated in 1528 schizophrenia patients. In patients receiving more than 820 mg chlorpromazine (CPZ), those with catatonic-type disorder had significantly (p<0.05) higher ND scores than those in any of the other diagnostic subtypes. Even in patients receiving 450 mg CPZ or more, catatonic patients had significantly (p=0.046) higher ND scores than other patients. Patients with catatonic schizophrenia are highly vulnerable to negative symptoms related to neuroleptic drugs, probably because of a defect in their dopaminergic neuronal pathways.
Salokangas
Raimo K R
RK
Department of Psychiatry, University of Turku, FIN-20520 Turku, Finland. Raimo.K.R.Salokangas@tyks.fi
Honkonen
Teija
T
Stengård
Eija
E
Koivisto
Anna Maija
AM
Hietala
Jarmo
J
D000293:Adolescent; D000328:Adult; D000704:Analysis of Variance; D014150:Antipsychotic Agents / Q000009:adverse effects*; D002746:Chlorpromazine / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012559:Schizophrenia / Q000188:drug therapy; D012560:Schizophrenia, Catatonic / Q000188:drug therapy* / Q000523:psychology*; D012565:Schizophrenic Psychology
D014150:Antipsychotic Agents; D002746:Chlorpromazine